Spyre Therapeutics Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases

Reuters

2025/06/17

Spyre <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases

Spyre Therapeutics, Inc. $(SYRE)$, a clinical-stage biotechnology company, has announced positive interim results from its Phase 1 trials for two novel extended half-life monoclonal antibodies, SPY002 and SPY072, targeting TL1A. These results were presented on June 17, 2025, during a conference call and webcast. The antibodies demonstrated good tolerability, a half-life of approximately 75 days, and effective target engagement for up to 20 weeks. In addition, Spyre has initiated the SKYLINE-UC platform trial, evaluating treatments for ulcerative colitis, and plans to start the SKYWAY-RD basket trial in Q3 2025, which will assess SPY072 in several rheumatologic conditions. Topline proof-of-concept data are expected in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA11863) on June 17, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2544096170"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544096170\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544096170?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-17 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544096170","market":"nz","top_or_hot":-1,"title":"Spyre Therapeutics Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Spyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Spyre Therapeutics, Inc. <a href=\"https://laohu8.com/S/SYRE\">$(SYRE)$</a>, a clinical-stage biotechnology company, has announced positive interim results from its Phase 1 trials for two novel extended half-life monoclonal antibodies, SPY002 and SPY072, targeting TL1A. These results were presented on June 17, 2025, during a conference call and webcast. The antibodies demonstrated good tolerability, a half-life of approximately 75 days, and effective target engagement for up to 20 weeks. In addition, Spyre has initiated the SKYLINE-UC platform trial, evaluating treatments for ulcerative colitis, and plans to start the SKYWAY-RD basket trial in Q3 2025, which will assess SPY072 in several rheumatologic conditions. Topline proof-of-concept data are expected in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA11863) on June 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spyre Therapeutics Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpyre Therapeutics Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-17 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Spyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Spyre Therapeutics, Inc. <a href=\"https://laohu8.com/S/SYRE\">$(SYRE)$</a>, a clinical-stage biotechnology company, has announced positive interim results from its Phase 1 trials for two novel extended half-life monoclonal antibodies, SPY002 and SPY072, targeting TL1A. These results were presented on June 17, 2025, during a conference call and webcast. The antibodies demonstrated good tolerability, a half-life of approximately 75 days, and effective target engagement for up to 20 weeks. In addition, Spyre has initiated the SKYLINE-UC platform trial, evaluating treatments for ulcerative colitis, and plans to start the SKYWAY-RD basket trial in Q3 2025, which will assess SPY072 in several rheumatologic conditions. Topline proof-of-concept data are expected in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA11863) on June 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SYRE","symbol_name":"SPYRE THERAPEUTICS INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL2NYgl5:1","article_id":"2544096170","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544096170","pubTimestamp":1750159845,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Spyre Therapeutics Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases. Spyre Therapeutics, Inc. , a clinical-stage biotechnology company, has announced positive interim results from its Phase 1 trials for two novel extended half-life monoclonal antibodies, SPY002 and SPY072, targeting TL1A. These results were presented on June 17, 2025, during a conference call and webcast. The antibodies demonstrated good tolerability, a half-life of approximately 75 days, and effective target engagement for up to 20 weeks. In addition, Spyre has initiated the SKYLINE-UC platform trial, evaluating treatments for ulcerative colitis, and plans to start the SKYWAY-RD basket trial in Q3 2025, which will assess SPY072 in several rheumatologic conditions. Topline proof-of-concept data are expected in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUB","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SYRE":"SPYRE THERAPEUTICS INC","BK4139":"生物科技"},"translate_title":"Spyre Therapeutics宣布TL1A抗体项目1期中期结果积极，并启动炎症和风湿病2期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYRE":0.9},"content_text":"Spyre Therapeutics Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases\n    \n\n        Spyre Therapeutics, Inc. $(SYRE)$, a clinical-stage biotechnology company, has announced positive interim results from its Phase 1 trials for two novel extended half-life monoclonal antibodies, SPY002 and SPY072, targeting TL1A. These results were presented on June 17, 2025, during a conference call and webcast. The antibodies demonstrated good tolerability, a half-life of approximately 75 days, and effective target engagement for up to 20 weeks. In addition, Spyre has initiated the SKYLINE-UC platform trial, evaluating treatments for ulcerative colitis, and plans to start the SKYWAY-RD basket trial in Q3 2025, which will assess SPY072 in several rheumatologic conditions. Topline proof-of-concept data are expected in 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA11863) on June 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}